Related Experiment Video
Updated: Sep 1, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Atom-based 3D-QSAR and DFT analysis of 5-substituted 2-acylaminothiazole derivatives as HIV-1 latency-reversing
Mohammad Aqueel Khan1, Sanjeev Kumar Singh1
1Department of Bioinformatics, Computer Aided Drug Design and Molecular Modelling Lab, Alagappa University, Karaikudi, Tamil Nadu, India.
Abstract:
HIV-1 latency consists of viral DNA; integrated inside the host genome; it remains transcriptional silent. Combined Antiretroviral Therapy (cART) and the host immune system fail to recognize the latency cells or reservoirs, representing a major barrier to eradicating the HIV-1 infection. The Shock and Kill emerged as a promising strategy to target these cells using Latency reversal agents (LRAs); partially succeeded in producing viral mRNA but failed to reduce the size of reservoirs. In this Context, 2-acylaminothiazole class derivatives appeared as promising HIV-1 latency-reversing agents. In this study, we have developed an atom-based 3 D-QSAR model by utilizing the 49 active compounds of the 5-substituted 2-acylaminothiazoles derivatives. These compounds are further randomly divided into training (37) and test (12) datasets, yielding statistically significant R2 (0.90) and Q2 (0.85) results, respectively. The internal and external validation of the model shows highly robust and reliable results. Next, the model was visualized to check the favourable and unfavourable groups in terms of hydrogen bond donor, electron-withdrawing and hydrophobic group on the most active compound 96 and least active compound 30. The investigated model reveals the structural insights required for obtaining more leads that are potent. Finally, DFT calculations on the most and least active compounds were performed to support the atom-based 3 D-QSAR model. Overall, this study will aid in understanding the minimum structural requirement and functional group required for screening the novel potent leads as HIV-1 latency reversal agents.Communicated by Ramaswamy H. Sarma.

